Previous studies had examined the role of tumor markers in the diagnosis, treatment, and prognosis of other urinary tract tumors such as prostate-specific antigen (PSA) in prostate cancer (3) and chemokine receptor expression, including CXCR3 and CXCR2 in renal cell carcinoma (4). This evidence concerns the gene KLK3 and prostate cancer.